CircESRP1 inhibits clear cell renal cell carcinoma progression through the CTCF-mediated positive feedback loop

Lin-Jing Gong, Xin-Yuan Wang, Xu-dong Yao, Xu Wu and Wen-Yu Gu

© The Author(s) 2021

INTRODUCTION

Renal cell carcinoma (RCC) is one of the most common but lethal urological tumors, accounting for 2–3% of adult malignancies [1]. Generally, clear cell RCC (ccRCC) comprises 80–90% of RCC, and is reported as the most common histologic subtype with higher invasive ability and relapse rate [2]. Accumulating evidence has demonstrated ~20–30% of patients present with metastatic disease at initial diagnosis [3, 4]. Moreover, ccRCC resists radiotherapy and chemotherapy after primary radical surgery [5–7]. Thus, it is urgent to elucidate the potential molecular mechanisms underlying malignant ccRCC and determine effective therapeutic strategies.

Circular RNAs (circRNAs) are covalently closed continuous loops formed by back-splicing, most commonly derived from the exon or intron of gene precursor mRNA (pre-mRNA) [8]. Regarding the unique structures and high stability, circRNAs could bind to RNA-associated proteins and regulate transcription by competing with linear splicing [9, 10], and also act as protein decoys or miRNA sponges to assume their roles of competing endogenous RNAs (ceRNAs) [11, 12], thereby identified as important molecules in biological processes and tumor progression [13]. Recently, an increasing number of circRNAs have been reported to be associated with malignant behavior in ccRCC. For instance, Li and his colleague demonstrated that circTLK1 played a vital role in the RCC progression and patients with higher level of circTLK1 represented a poor prognosis [14]. Moreover, it has been identified circPTCH1 as a novel target for therapeutic intervention of metastatic RCC, as it could promote RCC metastasis via activating the EMT process [15]. However, only a few upregulated circRNAs have been characterized, and the suppressive phenotype of circRNAs in RCC is largely unknown.

As a ubiquitously expressed transcription factor, CCCTC-binding factor (CTCF) is reported to be associated with malignant behavior in tumors [16]. Meanwhile, it has been shown to participate more or less in the regulation of EMT pathway [17]. Recent year, some studies indicated that CTCF may affect the progression of RCC and influenced the prognosis of those patients [18]. Nevertheless, whether CTCF regulates ccRCC-relevant circRNAs and the potential molecular mechanisms remain unknown.

In the present study, the expression profiles of circRNAs in RCC tissues from GEO database were analyzed. A novel circRNA that derived from the ESRP1 gene locus at 8q22.1 exons was identified to be implicated in a variety of human diseases including cancers. However, the underlying molecular mechanism of circRNA regulating the progression of renal cell carcinoma (RCC) remains largely unclear. In the present study, we identified a novel circular RNA, circESRP1, that derived from the ESRP1 gene locus at 8q22.1 exons. Lower expression of circESRP1 was found in clear cell RCC (ccRCC) tissues and cell lines. Besides, circESRP1 expression level showed inversely correlated with the advanced tumor size, TNM stage and distant metastasis of ccRCC. The expression level of circESRP1 exhibited a positive correlation with CTCF protein but negatively correlated with miR-3942 in 79 ccRCC tissues. In vivo experiments, we found that overexpression of circESRP1 effectively repressed xenograft tumor growth and inhibited c-Myc-mediated EMT progression. CircESRP1 acted as a sponge to competitively bind with miR-3942 as confirmed through RNA pull-down, RIP and dual-luciferase reporter assays. Moreover, CTCF, a downstream target of miR-3942, was validated to specifically promote the circESRP1 transcript expression and regulated by circESRP1/miR-3942 pathway to form a positive feedback loop. We also revealed that the circESRP1/miR-3942/CTCF feedback loop regulated the ccRCC cell functions via c-Myc mediated EMT process. This study provides a novel regulatory model of circRNA via forming a positive-feedback loop that perpetuates the circESRP1/miR-3942/CTCF axis, suggesting that this signaling may serve as a novel target for the treatment of ccRCC.

Cell Death and Disease (2021)12:1081 ; https://doi.org/10.1038/s41419-021-04366-4
MATERIALS AND METHODS

Human tissue specimens

The pairs of snap-frozen ccRCC tissues and paired adjacent normal kidney tissues were collected between January 2015 and December 2018 for validation. Histological and pathological diagnoses of the specimens were confirmed according to the 2016 World Health Organization Consensus Classification and Staging System of Renal Tumor and Fuhrman grade by two experienced pathologists. All specimens were obtained with appropriate informed consent of the patients and approved by the Ethics Committee of Shanghai Tenth People’s Hospital of Tongji University, and written informed consent was obtained from all patients.

GEO data

Circular RNA filtering was carried out on Gene Expression Omnibus (GEO) database (GEO accession: GSE100186). A total of 4 paired ccRCC and matched non-tumor tissues were included in this circRNA expression dataset. The circRNA expression profile was calibrated and standardized using the R package at first, and then differentially expressed circRNAs were identified using the limma package with P < 0.05 and |log2FC|>2.

TCGA data analysis

miRNA expression data obtained from the TCGA were used to assess the different miRNAs level in KIRC (545 cases) and normal tissues (71 cases). The data analysis was performed by the Limma R package.

Cell lines

Human RCC cell lines 786-O, ACHN, Caki-1, A498, and normal kidney cell line HK-2 were purchased from the ATCC. All cell lines were expanded to passage 3, stored in liquid nitrogen, and used for fewer than 4 months after receipt or resuscitation from cryopreservation. Cells were cultivated in Roswell Park Memorial Institute (RPMI)-1640 medium containing 10% fetal bovine serum (Gibco, Grand Island) at 37 °C with 5% CO₂.

RNA-Fluorescence in situ hybridization

FISH assay was performed with Cy3-labeled circESRP1 (5'-AATAAGTTCCA TCTTGCAGGACAGCATTTATAAGG-3') and FITC-labeled miR-3942-5p probes (5'-ATTCTAGGTAACAGTTGGCTT-3') synthesized by GenePharma (Shanghai, China). The FISH staining was performed using a fluorescence in situ hybridization kit (Ribobio, Guangzhou, China) according to the manufacturer's protocol in ccRCC cells (786O, ACHN). 4',6-diamidino-2-phenylindole (DAPI, Beyotime, China) was administrated to stain the cell nuclei, and the subcellular distributions of circESRP1 and miR-3942-5p in ccRCC cells were photographed with a confocal laser scanning microscope (Nikon, Japan).

Sanger sequencing

RNA was extracted from RCC cells and the cDNA was reversely transcribed using the Takara PrimeScript RT Reagent Kit. Sanger sequencing was performed by the Geneseeed Biotech Company (Guangzhou, China).

Plasmid construction and cells transfection

The circESRP1-overexpressing lentivirus plasmid, miR-3942-5p mimics, and inhibitor were designed and synthesized by Ribobio (Guangzhou, China). Virus-containing supernatant was collected 48 h after lentivirus packaging, followed by its addition to the ccRCC cells. After 24 h incubation, the stably infected cells were selected with 2 μg/mL of Puromycin purchased from Selleck (Shanghai, China). CTCF small hairpin RNA (shRNA) plasmids (shCTCF-1, 5'-GCAATGGAGAATATTTAAAGG-3′; shCTCF-2, 5'-GGCGAAGGT GAACCCCATTGA-3') were synthesized by GenePharma (Shanghai, China). Full length of CTCF was constructed into pcDNA3.1 vector (Invitrogen, Carlsbad, USA) for overexpression of CTCF. Small-interfering RNA (siRNA) of c-Myc (5'-GAAGGACGACGAGAACAGAGUU-3') was synthesized by and purchased from Genechem (Shanghai, China). The transfection assays were conducted according to the manufacturer’s protocol by using Lipofectamine 2000.

EdU and colony formation assay

The proliferation potential of ccRCC cells was assessed using EdU and colony formation assay. For colony formation assays, 1000 cells in 2 ml medium were seeded in 6-well plates. For the EDU, the assay was conducted using EdU Apollo DNA in vitro kit (Ribobio, Guangzhou, China) following the manufacturers’ instructions. The results were detected under immunofluorescence microscope (Olympus IX73, Tokyo, Japan).

Cell invasion and transwell assay

Cell invasion and transwell assays were performed as described previously [19, 20]. The invaded or migrated cells were counted in ten randomly microscopic fields.

Wound healing assay

Wound healing assay was performed as previously reported [19], and the results were measured by Migration index using Image J software.

RNA extraction and qPCR assay

Total RNAs from tissues or cells were isolated using Trizol reagent (Invitrogen), and miRNA was extracted using the SanPrep Column microRNA Extraction Kit (Sangon, Shanghai, China). Cytoplasmic and nuclear RNAs was isolated using PARIS Kit (Life Technologies, ThermoFisher, Waltham, USA) according to the manufacturer's instructions. cDNA was synthesized using PrimeScript RT Reagent (Takara) or Mir-XTM miRNA First-Strand Synthesis kit (Takara, Kyoto, Japan). qRT-PCR was applied using a Bio-Rad CFX96 system (Bio-Rad, Foster City, CA, USA). The miRNAs and circRNAs expression in tissues or cell lines were normalized to GAPDH expression. The miRNAs expression was normalized to U6 expression. Relative RNA expression was calculated using the 2−ΔΔCT. The primers sequences used for qRT-PCR are shown in Table S1.

RNAse R resistance analysis of circESRP1 and actinomycin D treatment assay

The ccRCC cells were treated with or without RNAse R (4 U/μg, Epicenter, Madison, USA) and incubated for 30 min at 37 °C. To study the stability of circESRP1 and linear ESRP1, the quantification of their half-lives was detected using actinomycin D treatment assay. The ccRCC cells were exposed to Actinomycin D (2 μg/mL) for 0, 4, 8, 12, or 16 h to against new RNA synthesis. The relative expression levels of RNAs were measured using qRT-PCR assay.

Chromatin immunoprecipitation (ChIP)

To determine the cross-talking between CTCF and the ESRP1 promoter, a ChIP assay was performed according to Pierce Magnetic ChIP Kit (Thermo Scientific). Briefly, the DNA–protein complex obtained from 786O cells was sonicated to disassemble the cross-linked chromatin DNA fragments to be 200–1000 bp. Then, immunoprecipitation was implemented with 2 μg of anti-CTCF antibody (Abcam, Burlingame, CA, USA) and protein A-Sepharose beads. Meanwhile, IgG acted as a negative control. After washing the cross-links, the enriched ESRP1 promoter was purified and then analyzed by qRT-PCR with validated primers. The primer sequences were designed and synthesized by GenePharma (Shanghai, China). The qRT-PCR products were validated by agarose gel electrophoresis.

RNA pull-down

The biotinylated 3' end of miR-3942-5p mimic or control RNA (GenePharm Biotech) was transfected into ccRCC cells (100 nM). Two days after transfection, whole-cell lysates were harvested. The biotinylated RNA complex was pulled down by streptavidin magnetic beads at 4 °C on the rotator overnight. The abundance of circESRP1 in the bound fraction was evaluated by qRT-PCR.

RNA immunoprecipitation (RIP) assay

The Argonaute-2 (AGO2)-RIP assay was performed using the MagnaRIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, MA, USA). Briefly, ccRCC cells were harvested and lysed in RIP lysis buffer, and then incubated with magnetic beads coated with 5 μg of control rabbit IgG or antibody against AGO2 (Abcam, MA, USA) with rotation at 4 °C overnight. The immunoprecipitated RNAs were extracted as described above and detected by qRT-PCR.
Luciferase reporter assay
The potential binding sites of miR-3942-5p and circESRP1 or CTCF were obtained from miRanda (http://www.microrna.org/) and TargetScan (http://www.targetscan.org/). Then the wild type (WT) and mutant (MUT) containing the predicted sequences were cloned into the luciferase reporter vector (Promega, Madison, WI, USA). ccRCC cells were then co-transfected with WT or MUT luciferase reporter vector with miR-3942-5p or control miRNA. For the luciferase promoter assay, the ESRP1 promoter WT or MUT luciferase reporter vector was co-transfected with CTCF plasmid or control pRL-TK Renilla plasmid into ccRCC cells. After 48 h, the firefly luciferase activities were determined comparing to Renilla using Dual-Luciferase Reporter Assay System (Promega).

Western blot
Proteins were separated by electrophoresis and then transferred to PVDF membrane for the incubation with primary antibodies, including anti-E-cadherin (1:1000, Cell Signaling Technology, #3195), anti-N-cadherin (1:1000, Cell Signaling Technology, #13116), anti-Claudin-1 (1:1000, Cell Signaling Technology, #13255), anti-CTCF (1:1000, Cell Signaling Technology, #3418), and anti-c-Myc (1:1000, Cell Signaling Technology, #9402). GAPDH (1:500, Beyotime Biotechnology, AF1186) acted as the internal control. After incubation overnight at 4 °C, the immunoreactive blots were washed and administrated with HRP-conjugated secondary antibodies at room temperature for 1 h. Finally, the blots were detected by ECL (Beyotime Biotechnology).

In vivo xenograft experiment
The animal experiment was approved by the Ethics Committee of Shanghai Tenth People’s Hospital of Tongji University. ACHN cell line stably expressing firefly luciferase was constructed. The male BALB/c nude mice (6- to 8-week old) were purchased and randomly divided into two groups (n = 4 per group) for subcutaneously injection of 1 × 10⁶ Luc-ACHN cells (Vector or OE-circESRP1). Tumor progress was observed using the IVIS imaging system (PerkinElmer, USA) for once a week. Subsequently, the mice were sacrificed 5 weeks later. The harvested organs were immediately excised and weighted. Last, these tumors were assessed for IHC staining and PCR assay.

In vivo metastatic model
The male BALB/c nude mice (6- to 8-week old) were cared for based on our institute’s protocols for ethical animal care, and the experiment was approved by the Ethics Committee of Shanghai Tenth People’s Hospital of Tongji University. Mice were randomly assigned into two groups, control and experimental groups (n = 6 per group). A total of 1 × 10⁶ ACHN cells (Vector or OE-circESRP1) were suspended in 100 μl of sterile PBS and administrated to mice through tail vein injections. Then, all mice were sacrificed for histological examination of lung metastases after 4 weeks of tail vein injections.

Immunohistochemistry (IHC)
Tumor tissues of patients or mice were fixed in 10% (v/v) formaldehyde in PBS, embedded in paraffin, and cut into 4-μm sections and used for IHC staining with specific primary antibodies against PCNA (1:200, Cell Signaling Technology), c-Myc (1:500, Abcam), Vimentin (1:200, Cell Signaling Technology), E-cadherin (1:400, Cell Signaling Technology), and CTGF (1:1000, Cell Signaling Technology). The representative images were acquired under a light microscope (Olympus IX73, Tokyo, Japan). Positive degree was calculated as the number of immunopositive cells × 100% divided by the total number of cells/field in 10 random fields at ×400 magnification.

Statistical analysis
All experiments were performed at least three times. The data were presented as means ± SEM. Statistical analyses were conducted using SPSS software (Version 25.0) and GraphPad Prism (Version 7.0). Group differences were tested for statistical significance using Student’s t-test (two-tailed), one-way analysis of variance (ANOVA), Chi-square test (the frequency test), and Spearman’s correlation, as appropriate. P < 0.05 was considered statistically significant.

RESULTS

circESRP1 is lowly expressed in the RCC tissue and cells
In this study, we first analyzed the circRNA gene chip GSE100186 from GEO database (https://www.ncbi.nlm.nih.gov/geo/). Among these differentially expressed circRNAs, we focused on circESRP1, which was identified to be aberrantly lowly expressed in RCC cancer (Fig. 1A). Previous study has demonstrated that circESRP1 served as a vital biomarker of chemosensitivity in small cell lung cancer (SCLC) patients [21]. However, the potential functions in RCC patients remained unknown. As shown in Fig. 1B, circESRP1 was derived from the ESRP1 gene (chr8:95676924–95677424) and generated from its exons 7, 8, and 9 via back-splicing. After predicting the sequence of circESRP1 back-splicing junction on circBase (http://www.circbase.org/), we designed a specific primer and validated the back-splicing junction of circESRP1 by Sanger sequencing. The presence of circESRP1 was also proved by qRT-PCR and agarose gel electrophoresis. Overall, we made the validation of characterization for circESRP1 in RCC tissue and cells. In line with previous finding, qRT-PCR analysis suggested circESRP1 expression was notably decreased in 79 paired RCC tissues compared with adjacent non-tumor tissues (ANT, Fig. 1C). Similar findings were also observed in ccRCC and HK2 cell lines analyzed by qRT-PCR, as shown in Fig. 1D. To further verify the stability of circESRP1 in ccRCC cells (786O, ACHN), we treated cells with Actinomycin D or RNase R, respectively. After the ccRCC cells were treated with Actinomycin D, circESRP1 exhibited an obviously longer half-life than did linear transcript (Fig. 1E). Moreover, as illustrated in Fig. 1F, circESRP1 was able to be more resistant to RNase R degradation, suggesting the circular structure of circESRP1 in ccRCC cells. Next, the subcellular localization of circESRP1 was assessed in ccRCC cells (786O, ACHN) by nuclear-cytoplasmic fractionation assay. The results showed that circESRP1 transcripts were located predominantly in the cytoplasm (Fig. 1G).

Overexpression of circESRP1 inhibits RCC progression in vitro
To determine the biological function of circESRP1, circESRP1-overexpressing lentivirus plasmid (OE-circESRP1) and the control vector (Vector) were transfected to ccRCC cells (786O and ACHN). After gaining the stable cell strains, the results of qRT-PCR presented that the expression of linear ESPR1 mRNA were not influenced by the OE-circESRP1 transfection (Fig. 2A). Then, we performed the colony formation assay, Edu assay, transwell assay, and wound healing assay to identify the potential antiangiogenic roles of circESRP1 in vitro. Capabilities of proliferation, migration, and invasion of ccRCC Cells were considerably attenuated after overexpression of circESRP1, while it was higher in the circESRP1 empty control vector group (Fig. 2B–E). Subsequently, we further tested the protein marks of epithelial-mesenchymal transition (EMT) by western blot analysis. According to the results from Fig. 2F, immunoblotting showed that overexpression of circESRP1 significantly enhanced the expression of epithelial markers (E-cadherin, Claudin-1), while inhibited the levels of mesenchymal markers (N-cadherin). Taken together, these data supported that upregulation of circESRP1 exhibited antioncogenic effects on RCC tumorigenesis in vitro.

CTCF binds to the ESRP1 promoter and enhances circESRP1 expression
After identified the role of circESRP1 in ccRCC progression, we wondered how circESRP1 was regulated during the pathophysiological process of ccRCC tumorigenesis. CCCTC-binding factor (CTCF) is a vital zinc finger transcription factor that participating in transcription regulation [22, 23]. We found that CTCF was predicted to be able to bind the promoter region of circESRP1 based on TRCirc (http://www.licpathway.net/TRCirc/view/index) [24]. According the public GEPIA dataset based on the TCGA (http://gepia.cancer-pku.cn/), the bivariate correlation analysis revealed a remarkable negative correlation between the CTCF mRNA expression and tumor stage in ccRCC Patients (Fig. 3A). Besides, patients with lower CTCF expression had poor overall survival (Fig. 3B). Therefore, we speculated that CTCF might mediate the biological function of RCC cells by promoting
circESRP1 transcription. The bioinformatics tools predicted on JASPAR (http://jaspar.genereg.net/) and PROMO 3.0 website validated that CTCF shared with the binding sites with the promoter region of ESRP1 (Fig. 3C). Simultaneously, targeting the two potential sites, the ChIP-PCR and agarose gel electrophoresis assays were performed. The result demonstrated that the second site (−257 to −239) might effectively combine with the CTCF antibody (Fig. 3D). Furthermore, the WT and MUT sequences of ESRP1 promoter region (−257 to −239) targeting the second predicted sites were constructed, and the results of luciferase reporter assay proved the WT rather than MUT of this region could combine with the CTCF, suggesting the CTCF-mediated activation for ESRP1 transcription (Fig. 3E).

The biogenesis of circular RNAs or linear ones can derive from the same pre-mRNA through the competition between back-splicing and canonical splicing [25]. Hence, we further investigated the relationships between the CTCF expression and circESRP1, or ESRP1 mRNA levels. As shown in Fig. 3F, there was no significant correlation between CTCF and ESRP1 in the KIRC tissues from GEPIA dataset (p = 0.89). Nevertheless, in the enrolled RCC patients, we found that the circESRP1 expression was positively correlated with CTCF (p < 0.001, Fig. 3G). The expression of ESRP1 linear RNA showed no significant correlation with the expression of circESRP1 (p = 0.7202, Fig. S1). Next, 786O and ACHN cells were transfected with the shRNAs or pcDNA-CTCF before the assays. The transfection efficiency was examined by qRT-PCR (Fig. 3H, I) and western blot (Fig. S2). Similarly, CTCF overexpressed plasmid enhanced ESRP1 circular levels rather than ESRP1 mRNA, and CTCF silencing shRNA reduced circESRP1 level rather than linear ESRP1 in both 786O ACHN cells (Fig. 3J, K). Taken together, our results indicated that CTCF specifically regulated the expression of circESRP1 instead of ESRP1 mRNA.

miR-3942 functions as the bridge of circESRP1/CTCF axis

Next, we wondered whether circESRP1 could regulate the expression levels of CTCF to form a closed-loop regulation
Recent studies have reported that circRNAs can function as miRNA sponges to regulate gene expression [26, 27]. RNA immunoprecipitation (RIP) analysis revealed that circESRP1 was significantly enriched by the AGO2 antibody (Fig. 4A, \( P < 0.05 \)), suggesting that circESRP1 may act as a ceRNA in the pathogenic process of RCC. To explore the candidate miRNAs that contained putative targeting regions for CTCF, 1078 miRNAs were selected from the prediction results through TargetScan (http://www.targetscan.org/) and miRDB (http://mirdb.org/). Meanwhile, online bioinformatics tool CSCD (http://gb.whu.edu.cn/CSCD/).

Fig. 2 Overexpression of circESRP1 suppressed renal cancer progression. A ccRCC cells that stably overexpressed circESRP1 were constructed. The circESRP1 and linear ESRP1 mRNA level were measured using qRT-PCR. B Colony formation assay was performed in both 786O and ACHN cell lines after overexpression with circESRP1. C Cell proliferation rate in ccRCC cells (786O, ACHN) under the specific conditions was performed by EdU assay. Scale bar: 100 μm. D, E The biological role of circESRP1 on cell migration and invasion capability was assessed by wound healing assay (D, scale bar: 200 μm), transwell migration assay, and matrigel invasion assay (E, scale bar: 50 μm) in 786O and ACHN cells, respectively. F The protein markers of EMT, including mesenchymal markers (N-cadherin) and the epithelial marker (E-cadherin, Claudin-1), were measured by western blot analysis. Data are the means ± SEM of three independent experiments. *\( p < 0.05 \); **\( p < 0.01 \).

relationship. Recent studies have reported that circRNAs can function as miRNA sponges to regulate gene expression [26, 27]. RNA immunoprecipitation (RIP) analysis revealed that circESRP1 was significantly enriched by the AGO2 antibody (Fig. 4A, \( P < 0.05 \)), suggesting that circESRP1 may act as a ceRNA in the pathogenic process of RCC. To explore the candidate miRNAs that contained putative targeting regions for CTCF, 1078 miRNAs were selected from the prediction results through TargetScan (http://www.targetscan.org/) and miRDB (http://mirdb.org/). Meanwhile, online bioinformatics tool CSCD (http://gb.whu.edu.cn/CSCD/)
indicated that there were 49 miRNAs with potential binding sites for circESRP1. Subsequently, we conducted a miRNA sequencing data analysis to evaluate the miRNA expression profiles of RCC downloaded from TCGA (Fig. 4B, C). The results revealed 316 differentially expressed miRNAs in the 71 normal and 545 RCC tissues (|fold changes| ≥ 1 and FDR < 0.05, Fig. 4D). Finally, the intersection between bioinformatic algorithms and upregulated miRNAs in TCGA datasets identified that miR-3942 might act as the target of circESRP1 and also highly expressed in ccRCC tissues (Fig. 4D, E). As expected, pull-down assays revealed significantly higher circESRP1 enrichment by biotin-miR-3942 (Fig. 4F, P < 0.05). Besides, the expression of miR-3942 was remarkably decreased after 786O and ACHN cells that overexpressed circESRP1 (Fig. 4G).

To observe the cellular distribution of circESRP1 and miR-3942-5p in the cytoplasm (Fig. 4H). Furthermore, circESRP1 was validated to be negatively correlated with the miR-3942 in RCC individuals (Fig. 4I).
In conclusion, the findings in this part manifested that circESRP1 may positive feedback regulate CTCF expression via serving as a sponge of miR-3942.

circESRP1 acts as a sponge of miR-3942 to regulate CTCF expression

To further determine the miRNA sponge ability of circESRP1, wild-type or mutant sequences corresponding with the miR-3942 were constructed (Fig. 5A). After co-transfection of miR-3942 mimic and circESRP1 wild type luciferase reporters into ccRCC cells, the luciferase activity was significantly reduced by ~35%, indicative of the directly binding capability of miR-3942 to circESRP1 (Fig. 5B). Given that the publicly available algorithms (TargetScan, miRDB) identified CTCF as a target of miR-3942 were detected by qRT-PCR. H The co-localization of miR-3942-5p and circESRP1 was observed by RNA in situ hybridization in 786O and ACHN cells. Nuclei were stained with DAPI. Bar = 100 μm. I Correlation between relative circESRP1 expression and relative miR-3942 expression was analyzed with Spearman’s analysis in 79 RCC clinical samples. *p < 0.05; ****p < 0.0001.

the interaction within CTCF and miR-3942-5p, we transfected the miR-3942-5p mimics and inhibitor into the ccRCC cells using Lipofectamine 2000. The transfection effectiveness of miR-3942 mimic and inhibitor were verified by qRT-PCR (Fig. 5C). Western blot analysis illustrated that miR-3942 mimic transfection repressed the CTCF protein, while the transfection of miR-3942 inhibitor markedly upregulated the protein level of CTCF (Fig. 5E, F). Therefore, these data support that CTCF expression level was negatively regulated by miR-3942-5p and functioned as the target of miR-3942 in ccRCC cells. We further determined whether the circESRP1 might involve in RCC tumor progression through circRNA–miRNA–mRNA signal pathway. For ccRCC cells, the transfection of OE-circESRP1 enhanced the expression of CTCF, while the co-transfection of miR-3942 mimic neutralized it (Fig. 5G, H). Taken together, these findings indicated that circESRP1 and miR-3942 had opposite effects on the CTCF expression. In addition, circESRP1 Inhibited RCC progression, at least in part through serving as a miR-3942 sponge to upregulate CTCF.
circESRP1 inhibits EMT by enhancing the suppressive effects of CTCF on c-Myc expression

EMT can increase malignant potential and aggressiveness of RCC. It has been confirmed that c-Myc is a transcription factor for the EMT progression in RCC [28, 29]. As CTCF was initially identified as a transcriptional repressor of the c-Myc gene [30], we speculated that interaction of CTCF with circESRP1/miR-3942 might modulate c-Myc expression and further affected the tumor phenotypes of RCC. In ccRCC cells (786O, ACHN), the pcDNA-CTCF or c-Myc siRNA transfection repressed the protein level of c-Myc. Interestingly, after the co-transfection of c-Myc overexpressed plasmid with pcDNA-CTCF, the decreased c-Myc protein level can be significantly recovered (Figs. 6A, B, S2D-E). Therefore, these findings proved CTCF could negatively regulate the c-Myc expression in ccRCC cells. Subsequently, rescue experiments were performed to identify the role of circESRP1/miR-3942-CTCF pathway and c-Myc-mediated EMT process. The transfection of pcDNA-CTCF or c-Myc siRNA could markedly inhibit the proliferation rate of 786O and ACHN cells compared with negative control (NC) group. The results of our study showed that overexpression of circESRP1 repressed the tumor phenotypes of RCC in vitro, however, the co-transfection of shCTCF or miR-3942 mimic can enhance the proliferation rate of ccRCC cells. In addition, the deficiency of c-Myc caused a significant reduction in cell proliferation.
proliferous abilities in most situations (Fig. 6C, D). Next, we performed wound healing assay (Fig. 7A, B), transwell invasion assay (Fig. 7C, D), and EMT marker assessment (Fig. 7E) for RCC malignant phenotype. Consistently, the cells transfected with pcDNA-CTCF and c-Myc siRNA showed lower migratory abilities, invasive abilities, and EMT characteristics compared with NC group (Fig. 7). The circESRP1 overexpression could rescue these tumor behaviors, while the co-transfection of shCTCF or miR-3942 mimic accelerated the migration, invasion, and EMT characteristics. Also, the deficient c-Myc expression could restrain the phenotype upon miR-3942 overexpression. Hence, these data identified the role of circESRP1/miR-3942/CTCF axis and c-Myc-mediated EMT process for RCC tumor behavior.

**Overexpression of circESRP1 restricts the RCC tumor growth, metastasis, and EMT markers expression in vivo**

The stably overexpressed circESRP1 that labeled with firefly luciferase in ACHN cells was conducted for the xenograft. As shown in Fig. 8A–D, in vivo studies of nude mice indicated that circESRP1 overexpression significantly decreased the tumor size (Fig. 8E, F) and reduced the tumor burden (Fig. 8G, H). These results suggest that circESRP1 might be a potential therapeutic target for RCC treatment.

**Fig. 6  circESRP1 prohibits ccRCC proliferation via miR-3942/CTCF axis and c-Myc.** A, B Western blot analysis showed the c-Myc protein level in the transfection of CTCF overexpressed plasmid with or without CMYC overexpression in ccRCC cells (786O, ACHN). C, D The DNA synthesis of 786O and ACHN cells was tested by EdU assay with the transfection of CTCF overexpressed plasmid (CTCF), CTCF shRNA (shCTCF), circESRP1-overexpressing lentivirus plasmid (circESRP1), c-Myc siRNA (si-c-Myc), and miR-3942 mimic. The data are presented as the mean (n = 3) ± SEM. *p < 0.05; **p < 0.01.
Fig. 7  circESRP1/miR-3942/CTCF positive feedback loop modulates ccRCC metastasis. A, B The migrative ability of 786O and ACHN cells was detected using wound healing assay with the transfection of CTCF overexpressed plasmid (CTCF), CTCF shRNA (shCTCF), circESRP1-overexpressing lentivirus plasmid (circESRP1), c-Myc siRNA (si-c-Myc), and miR-3942 mimic. Scale bar: 200 μm. C, D The invasive ability of 786O and ACHN cells was detected by matrigel invasion assay. Scale bar: 50 μm. E Western blot showed expression of different epithelial and mesenchymal markers (N-cadherin, E-cadherin, and Claudin-1). The data are presented as the mean (n = 3) ± SEM. *p < 0.05; **p < 0.01.
Fig. 8 Overexpression of circESRP1 inhibits the tumor growth and EMT signaling pathway of clear cell renal cell carcinoma (ccRCC) in vivo. A Overexpressed circESRP1 ACHN cells were injected subcutaneously to detect in vivo effect of circESRP1. B The tumor weight in circESRP1 overexpressed and control group. C Representative bioluminescence images of mice bearing ACHN cells were obtained. D Effect of circESRP1 expression level on ccRCC tumor volume in xenograft tumor mice. E Immunohistochemical staining of the tumor tissues showed that circESRP1 overexpression inhibited the tumor phenotypes of RCC. Bar = 50 μm. F Immunohistochemical staining for CTCF, E-cadherin, and Vimentin in ccRCC tissues and adjacent non-tumor tissues was shown. G A Schematic Diagram of circESRP1/miR-3942/CTCF feedback loop in ccRCC cells EMT. *p < 0.05; **p < 0.01.
volume and weight. Similar results were obtained using the bioluminescence in vivo imaging system. Then, the relative expressions of circESRP1, miR-3942, and CTCF were determined by qRT-PCR in Fig. S3, suggesting the presence of correlation in vivo. Furthermore, IHC staining revealed that intratumoral injection of overexpressed circESRP1 enhanced the E-cadherin expression, but decreased the levels of PCNA, c-Myc, and Vimentin, indicative of lower aggressive capabilities of tumor growth and metastasis (Fig. 8F). To further access the role of circESRP1 in ccRCC metastasis in vivo, mice were intravenously injected with ACHN cells. Overexpression of circESRP1 markedly increased pulmonary metastatic nodules compared with control group (Fig. S4). Taken together, these results indicated that circESRP1 played a critical role in RCC tumor growth and metastasis in vivo.

**Lower circESRP1 expression in RCC tissues predicts a poor prognosis**

To investigate the correlation between circESRP1 expression and clinic-pathological features, we divided enrolled individuals into two groups based on circESRP1 expression value. Chi-square test was performed to analyze clinical characters between the two groups. As shown in Table 1, circESRP1 level was correlated with tumor size (p = 0.002), distant metastasis (p = 0.001) and TNM stage (p = 0.001), but not with age (p = 0.077), sex (p = 0.079), or ISUP grade (p = 0.077). It suggested that high circESRP1 expression was associated with favorable clinical outcomes. Compared to the ANT tissues, the CTCF and E-cadherin stainings were weak, while Vimentin expression was robust in the ccRCC tissues (Fig. 8F). Besides, we noticed the obvious positive correlations between the levels of circESRP1 and E-cadherin expression in ccRCC tissues, but the negative correlation existed between levels of circESRP1 and Vimentin expression (Fig. S5). Based on these findings, we proposed that circESRP1/miR-3942/CTCF positive feedback loop negatively affected the c-Myc-EMT signaling pathway in ccRCC tissues, thereby impacting the tumor behaviors of RCC (Fig. 8G).

**DISCUSSION**

The current study highlights the prognostic and therapeutic importance of circESRP1 in RCC tumorigenesis. Clinically, this termed circESRP1 was significantly downregulated in RCC tissues, thereby inversely correlated with the advanced TNM stage of ccRCC. In vivo studies of nude mice showed overexpression of circESRP1 effectively repressed xenograft tumor development and pulmonary metastasis, and inhibited c-Myc-mediated EMT progression by maintaining the low expression level of CTCF. Several circRNAs have been identified to be significantly dysregulated in RCC [31, 32]. In our research, we discovered that the ectopic lowly expressed circESRP1 was closely correlated with the poor prognosis of RCC patients.

As regarding the biogenesis of circRNAs, existing studies have demonstrated that multiple transcription factors could regulate the biogenesis of circRNA from the precursor-mRNA [33]. CTCF is proposed as a tumor suppressor in multiple cancers [34], thereby our qRT-PCR assay revealed its downregulation in RCC cell lines and tissues. The dominating circRNAs are generated from the exons of genes which are also transcribed to linear mRNA [8]. Interestingly, previous studies also indicated that not all the expression of circRNAs are dependent of related linear isoforms and some of circRNAs are more abundant than their linear transcripts [35]. In the mechanical investigation, ChIP-PCR and dual-luciferase reporter assays confirmed an interaction between transcription factor CTCF and the promoter region of ESRP1. Moreover, overexpression of CTCF significantly elevated the expression level of circESRP1, while the ESRP1 miRNA expression did not change significantly. As a result, our data revealed that CTCF could directly bind to the ESRP1 promoter and promote its transcription, then accelerating the circularization of circESRP1. However, in this case, it remains unclear how CTCF could specifically promotes the expression of circESRP1 but not linear RNA. It is speculated that this may be because ESRP1 is also an important splicing factor [20, 36, 37] or circRNA has higher stability [8, 35]. Recent years, convincing evidences has also linked CTCF to modulation of alternative splicing (AS) at both the transcriptome-wide level and individual transcript [38, 39]. Besides, Meng et al. also found that Twist1 could bind the Cul2 promoter to activate its transcription and to selectively promote expression of Cul2 circular RNA (circ-10720), but not mRNA in hepatocellular carcinoma [33]. They also indicated previous study found that some cassette exons are more favorably included in circRNAs than in linear mRNAs [40], may be the cause of this phenomenon. Anyhow, this is a very interesting finding that deserves further study in the future.

Some dysregulated circRNAs can absorb miRNA to modulate the expression of oncogenes or tumor suppressor genes in carcinogenesis and cancer development [27]. Thus, the cytoplasmic location of circESRP1 indicated the potential post-transcriptional regulation. Accumulation evidence showed that more and more non-coding RNA-associated positive feedback loops have been excavated to be closely related to tumorigenesis and progression [20, 21]. As the CTCF expression was positive correlated with circESRP1 level, we were curious whether CTFC/circESRP1 pathway was also involved in this molecular regulatory mode. GEO and bioinformatics analysis were subsequently applied to screen the target genes of circESRP1/CTCF. According to the results, we finally identified miR-3942 as one of the leading candidates. A previous study showed that miR-3942-5p overexpression promoted the disease progression [41]. Our results indicated that circESRP1 upregulated CTCF expression by relieving the post-transcriptional suppression capabilities of miR-3942, suggesting a positive feedback loop between CTCF and circESRP1/miR-3942 pathway in ccRCC. Functional experiments presented that circESRP1 or CTCF overexpression could inhibit RCC cell migration and invasion, and this effect was attenuated by

---

**Table 1. Correlation within circESRP1 expression and the clinicopathological characteristic of ccRCC patients.**

| Characteristics          | circESRP1 expression | P-value |
|--------------------------|----------------------|---------|
|                          | Low (n = 41)         | High (n = 38) | |
| Age (yrs)                |                      |         |
| ≤60                      | 14                   | 17      | 0.077 |
| >60                      | 27                   | 21      |       |
| Sex (n)                  |                      |         |
| Male                     | 13                   | 16      | 0.079 |
| Female                   | 28                   | 22      |       |
| Tumor size (cm)          |                      |         |
| ≤4                       | 22                   | 28      | 0.002 |
| >4                       | 19                   | 10      |       |
| ISUP grade               |                      |         |
| I or II                  | 30                   | 23      | 0.077 |
| III or IV                | 11                   | 15      |       |
| AJCC stage               |                      |         |
| I or II                  | 23                   | 29      | 0.001 |
| III or IV                | 18                   | 9       |       |
| Distant metastasis       |                      |         |
| No                       | 34                   | 37      | 0.001 |
| Yes                      | 7                    | 1       |       |

P-value <0.05 represents statistical differences.
a miR-3942 mimic. These data revealed the vital role of the circESRP1/miR-3942/CTCF axis in ccRCC.

As a critical oncogene, c-Myc and its downstream targets had been extensively studied in a variety of cancer types. CircESRP1 overexpression impaired the stimulating effects of CTCF knock-down on c-Myc and EMT. Previous studies proved that CTCF could interact with c-Myc promoter elements and represses its transcription [30, 37], thus the constructing of circESRP1/miR-3942-5p/CTCF feedback loop could finally inhibit RCC EMT progression via restricting the expression of c-Myc. Previous studies indicated that CTCF was a master regulator of gene expression, and the functions of which were complicated. It can function as a transcriptional activator and repressor, as well as a transcriptionally targets Wdr5 to mediate somatic cell reprogramming. Stem Cells Dev. 2017;26:743–50.

Kieffer-Kwon K, Tang Z, Mathe E, Qian J, Sung M, Li G, et al. Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation. Cell 2013;155:1507–20.

Tang Z, Li X, Zhao J, Qian F, Feng C, Li Y, et al. TRCirc: a resource for transcriptional regulation information of circRNAs. Brief Bioinform. 2019;20:2327–33.

Chen L, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12:381–8.

Zhong Y, Du Y, Yang X, Mo Y, Fan C, Xiong F, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018;17:79.

Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17:272–83.

Wang Y, Fu D, Chen Y, Su J, Wang Y, Li X, et al. G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas. Cell Death Dis. 2019;10:501.

Zhao B, Liu L, Mao J, Zhang Z, Wang Q, Li Q. PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis. Cell Death Dis. 2018;9:307.

Peng W, He R, Zhang Z, Yang L, Mo Y. LINCC00346 promotes pancreatic cancer progression through the CTCF-mediated Mcy transcription. Oncogene 2019;38:6770–80.

Xue D, Wang H, Chen Y, Shen D, Li J, Wang M, et al. Circ-AKT3 inhibits clear cell renal carcinoma metastasis via altering miR-296-3p/E-cadherin signals. Mol Cancer. 2019;18:158.

Meng J, Chen S, Han J, Qian F, Wang B, Zhong W, et al. Twist1 regulates vimentin through CuZi circular RNA to promote EMT in hepatocellular carcinoma. Cancer Res. 2018;78:4150–62.

Fiorentino FP, Giordano A. The tumor suppressor role of CTCF. J Cell Physiol. 2012;227:479–92.

Li X, Yang L, Chen L. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2017;61:1428–42.

Feng YL, Chen DQ, Vaziri ND, Guo Y, Zhao YF. Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis. Med Res Rev. 2019;40:54–78.

CONCLUSION

Taken together, our research identified the circESRP1 functioned as a suppressor of tumor progression and metastasis in RCC patients. CTCF specifically regulated by circESRP1/miR-3942 pathway could promote the circESRP1 transcript expression. We validated that the overexpression of circESRP1 restrained tumor progression both in vivo and in vitro by the downregulation of c-Myc-mediated EMT pathway via CTCF-dependent positive feedback loop. These findings shed light on the pathogenic mechanism of circESRP1 for ccRCC, providing potential therapeutic targets for ccRCC treatment.

DATA AVAILABILITY

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

REFERENCES

1. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PFA, Patard J, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51:1502–10.

2. Frey U, Moch H. A clearer view of the molecular complexity of clear renal cell carcinoma. Ann Rev Pathol. 2015;10:263–89.

3. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albigeis L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:71009.

4. Lalani AA, McGregor BA, Albigeis L, Choueiri TK, Motzer R, Powles T, et al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions. Eur Urol. 2019;75:100–10.

5. Longo R, D’Andrea MR, Sarmiento R, Salerno F, Gasparini G. Integrated therapy of kidney cancer. Ann Oncol. 2007;18:v141–v148.

6. De Felice F, Tombolini V. Radiation therapy in renal cell carcinoma. Crit Rev Oncol/Hematol. 2018;128:82–87.

7. Makhoff P, Joshi S, Ghatalla P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Mol Cancer Ther. 2018;17:1355–64.

8. Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20:675–91.

9. Han B, Chao J, Yao H. Circular RNA and its mechanisms in disease: From the bench to the clinic. Pharm Therapeut. 2018;167:31–44.

10. Yang F, Hu A, Li D, Wang J, Guo Y, Liu Y, et al. Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation. Mol Cancer. 2019;18:158.

11. Zeng W, Liu Y, Li WT, Li Y, Zhu JF. CircFND3C33 sequestres miR-193-5p to derepress TIMP3 and inhibit colorectal cancer progression. Mol Oncol. 2020;14:2960–84.

12. Li X, Ding J, Wang Y, Cheng Z, Zhu Q. NUDET21 regulates circRNA cyclization and ceRNA crosstalk in hepatocellular carcinoma. Oncogene 2020;39:989–1004.

13. Wang S, Zhang Y, Cai Q, Ma M, Jin LY, Weng M, et al. Circular RNA FOXP1 promotes tumor progression and Warburg effect in gallbladder cancer by regulating PKLR expression. Mol Cancer. 2019;18:145.

14. Li J, Huang C, Zou Y, Ye J, Yu J, Gui Y. CircTLK1 promotes the proliferation and metastasis of renal cell carcinoma by sponging mir-136-5p. Mol Cancer. 2020;19:103.

15. Liu H, Hu G, Wang Z, Liu Q, Zhang J, Chen Y, et al. circPVT1 promotes invasion and metastasis in renal cell carcinoma via regulating miR-485-5p/MMP14 axis. Theranostics 2020;10:10791–807.

16. Weintrob AS, Li CH, Zamudio AV, Sivoga AA, Hannett NM, Day DS, et al. YY1 is a structural regulator of enhancer-promoter loops. Cell 2017;171:1573–1588e28.

17. Sun Q, Zhang S, Zhao J, Han X, Wang H, Sun M. HIF-1α or HOTTIP/CTCF promotes head and neck squamous cell carcinoma progression and drug resistance by targeting HOXA9. Mol Ther - Nucleic Acids. 2020;20:164–75.

18. Mu Z, Dong D, Sun M, Li L, Wei N, Hu B. Prognostic value of YTHDF2 in clear cell renal cell carcinoma. Front Oncol. 2020;10:1556.

19. Gong L, Wu X, Li X, Ni X, Gu W, Wang X, et al. S1PR3 deficiency alleviates radiation-induced pulmonary fibrosis through the regulation of epithelial-mesenchymal transition by targeting miR-495-3p. J Cell Physiol. 2020;235:2310–24.

20. Zhao W, Cui Y, Liu L, Qi X, Liu J, Ma S, et al. Splicing factor derived circular RNA circUHRF1 accelerates oral squamous cell carcinoma tumorigenesis via feedback loop. Cell Death Differ. 2020;27:919–33.

21. Huang W, Yang Y, Wu J, Niu Y, Yao Y, Zhang J, et al. Circular RNA circESRP1 sensitises small cell lung cancer cells to chemotherapy by sponging miR-93-5p to inhibit TGF-β signalling. Cell Death Differ. 2020;27:1709–27.

22. Wang F, Han J, Wang L, Jing Y, Zhu Z, Hu D, et al. CCCTC-binding factor transcriptionally targets Wdr5 to mediate somatic cell reprogramming. Stem Cells Dev. 2017;26:743–50.

23. Kieffer-Kwon K, Tang Z, Mathe E, Qian J, Sung M, Li G, et al. Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation. Cell 2013;155:1507–20.

24. Li X, Yang L, Chen L. The biogenesis, functions, and challenges of circular RNAs. Nat Rev Genet. 2015;12:35.

25. Chen L, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12:381–8.
37. Alharbi AB, Schmitz U, Bailey CG, Rasko JEJ. CTCF as a regulator of alternative splicing: new tricks for an old player. Nucleic Acids Res. 2021;49:7825–38.
38. Ruiz-Velasco M, Kumar M, Lai MC, Bhat P, Solis-Pinson AB, Reyes A, et al. CTCF-mediated chromatin loops between promoter and gene body regulate alternative splicing across individuals. Cell Syst. 2017;5:628–637.e6.
39. Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski B, Kashlev M, et al. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 2011;479:74–79.
40. Zhang X, Dong R, Zhang Y, Zhang J, Luo Z, Zhang J, et al. Diverse alternative back-splicing and alternative splicing landscape of circular RNAs. Genome Res. 2016;26:1277–87.
41. Zhao J, Zou H, Han C, Ma J, Zhao J, Tang J. Circular RNA BARD1 (Hsa_circ_0001098) overexpression in breast cancer cells with TCDD treatment could promote cell apoptosis via miR-3942/BARD1 axis. Cell Cycle. 2018;17:2731–44.
42. Yang Y, Quitschke W, Vostrov AA, Brewer GJ. CTCF is essential for up-regulating expression from the amyloid precursor protein promoter during differentiation of primary hippocampal neurons. J Neurochem. 1999;73:2286–98.
43. Vostrov AA, Quitschke WW. The zinc finger protein CTCF binds to the APBbeta domain of the amyloid beta-protein precursor promoter. Evidence for a role in transcriptional activation. J Biol Chem. 1997;272:33353–9.
44. Gaiti F, Calcino AD, Tanurdzic M, Degnan BM. Origin and evolution of the metazoan non-coding regulatory genome. Dev Biol. 2017;427:193–202.
45. Phillips JE, Corces VG. CTCF: master weaver of the genome. Cell 2009;137:1194–211.
46. Ohlsson R, Renkawitz R, Lobanenkov V. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Oxford; 2001. pp. 520–7.

ACKNOWLEDGEMENTS
We are grateful to the editors, the reviewers, and our colleagues for their valuable comments and efforts.

AUTHOR CONTRIBUTIONS
GLJ, WX, and GWY designed and performed the experiments. GLJ, WX, and WXY analyzed the results. GLJ and WX organized the results and wrote the paper. YXD, GWY, and WX provided the tools and patient specimens and edited the manuscript. All authors participated in critical revision of the manuscript for important intellectual content.

FUNDING
This work was supported by National Natural Science Foundation of China (Grant/ Award numbers: 82000095, 81800089), the fund for Fundamental Research Funds for the Central Universities (22120180576), a research grant from Shanghai Tenth People’s Hospital to W.Y. Gu (2021SYPDRC033), and the clinical research fund of Zhongshan Hospital to Xu Wu (2020ZSQN083).

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS STATEMENT
All specimens were obtained with appropriate informed consent of the patients and approved by the Ethics Committee of Shanghai Tenth People’s Hospital of Tongji University, and written informed consent was obtained from all patients. Animal researches were executed in compliance with the Ethics Committee of Shanghai Tenth People’s Hospital of Tongji University.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-04366-4.
Correspondence and requests for materials should be addressed to Xu Wu or Wen-Yu Gu.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021